Immunitybio is trading 4.37% down now at $7.78 after broader biotech weakness reversed the sector’s previous-session rally.
- No fresh company-specific announcement was identified for August 20, 2026.
- Latest listed releases are the August 4 second-quarter results and August 10 vice-chairman appointment.
- XBI is down 2.47% and major indexes are lower, with profit-taking and risk-off sentiment appearing to drive the decline.